MARKET

BLPH

BLPH

Bellerophon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.450
-0.040
-0.89%
After Hours: 4.290 -0.16 -3.60% 19:57 07/29 EDT
OPEN
4.540
PREV CLOSE
4.490
HIGH
4.725
LOW
4.400
VOLUME
58.08K
TURNOVER
--
52 WEEK HIGH
13.47
52 WEEK LOW
3.790
MARKET CAP
42.30M
P/E (TTM)
-1.6128
1D
5D
1M
3M
1Y
5Y
2 Falling Knives to Catch
GuruFocus News · 07/06 14:46
Hedge Funds Are Coming Back To Bellerophon Therapeutics, Inc. (BLPH)
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshl...
Insider Monkey · 06/29 12:05
Walgreens (WBA) to Report Q3 Earnings: What's in Store?
Zacks.com · 06/28 11:25
BIIB, TALO among premarket losers
Portage Biotech PRTG -28% on stock offering.Daqo New Energy DQ -10% following a report that the U.S. is poised to bar some solar products made in China's Xinjiang region.Biogen BIIB -8% in sympathy with Lilly's Alzheimer’s therapy plan.
Seekingalpha · 06/24 12:22
45 Biggest Movers From Yesterday
Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.
Benzinga · 06/24 09:08
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc.
Benzinga · 06/23 17:22
Bellerophon Therapeutics and Entera Bio among healthcare gainers; Second Sight Medical Products and Adial Pharmaceuticals among losers
Gainers: Entera Bio ENTX +56%. Orphazyme ORPH +47%. Bellerophon Therapeutics (BLPH) +26%. HUTCHMED HCM +11%. Evaxion Biotech (EVAX) +8%.Losers: Gemini Therapeutics GMTX -32%. Second Sight Medical Products EYES -19%. Millendo Therapeutics (MLND) -17%. Keros...
Seekingalpha · 06/23 15:00
BRIEF-Bellerophon Appoints Naseem Amin, M.D. As Chairman Of Its Board Of Directors
reuters.com · 05/26 12:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLPH. Analyze the recent business situations of Bellerophon through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLPH stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 6.63M
% Owned: 69.78%
Shares Outstanding: 9.51M
TypeInstitutionsShares
Increased
11
97.81K
New
7
184.54K
Decreased
12
499.89K
Sold Out
6
68.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Director
Naseem Amin
Chief Executive Officer/Director
Fabian Tenenbaum
Chief Financial Officer/Secretary
Assaf Korner
Vice President - Operations
Parag Shah
Vice President
Martin Dekker
Vice President - Administration
Amy Edmonds
Other
Peter Fernandes
Independent Director
Scott Bruder
Independent Director
Mary Cloyd
Independent Director
Crispin Teufel
Independent Director
Theodore Wang
No Data
About BLPH
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.

Webull offers kinds of Bellerophon Therapeutics Inc stock information, including NASDAQ:BLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLPH stock methods without spending real money on the virtual paper trading platform.